Fierce Pharma

With FDA approval, Lilly’s BTK drug Jaypirca enters first-line CLL

Eli Lilly’s Jaypirca, the first noncovalent BTK inhibitor, has won FDA approval for the first-line treatment of chronic ...
Fierce Pharma

Pfizer's Tukysa snags first-line approval in HER2+ breast cancer maintenance

Pfizer bagged a coveted first-line maintenance approval for Tukysa. In combination with HER2 antibody drugs, the treatment ...
BIOENGINEER

New Leukemia Drug Shows Stunning First-Line Results, but Experts Urge Caution on Treatment Order

Chronic lymphocytic leukemia (CLL), the most common leukemia of adults in Western countries, is standing at a genuine ...

New drug approved in second-line after failing in first-line

Today's focus is on a new combination therapy for renal cell carcinoma approved by the US FDA on September 24, 2026. A drug ...